Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
Go back to Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors| (NASDAQ: RUBY) | Delayed: 0.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.08 | 52 Week High | $ | |||
| Open | $0.08 | 52 Week Low | $ | |||
| Day High | $0.08 | P/E | N/A | |||
| Day Low | $0.08 | EPS | $ | |||
| Volume | 396,845 | |||||
